期刊文献+

5-氨基水杨酸对炎症性肠病瘤变预防作用的meta分析报告 被引量:1

A meta-analysis of 5-aminosalicylic acid preventing the development of intestinal neoplasia in inflammatory bowel disease
下载PDF
导出
摘要 目的:对5-氨基水杨酸(5-ASA)干预炎症性肠病(IBD)相关性结肠癌(CRC)或上皮内瘤变(Dys)(IBD-CRC/Dys)的作用进行临床资料的评价和meta分析。方法:检索PubMed、Web of Science、the Cochrane Library等主要数据库,将符合标准的资料纳入研究,统计优势比(OR)及其95%置信区间(CI),并根据IBD类型和疗程进行亚组分析。结果:共纳入15篇文献中的5 038名IBD患者。使用5-ASA的IBD患者发生CRC/Dys的OR=0.53(95%CI:0.37~0.76)。根据疾病类型分层分析显示,使用5-ASA的溃疡性结肠炎患者发生CRC/Dys的OR=0.45(95%CI:0.27~0.77),克罗恩病患者发生CRC/Dys的OR=0.39(95%CI:0.16~0.97);此外,疗程小于1年的患者发生CRC/Dys的OR=0.59(95%CI:0.26~1.34),而疗程在1年以上(最长者达20年)发生CRC/Dys的OR=0.43(95%CI:0.25~0.74)。结论:5-ASA对IBD-CRC/Dys有预防作用,且该作用呈疗程依赖性,疗程长者效果明显,尚不能证明2~6个月的使用疗程有预防作用。 AIM: We conducted an evaluation of clinical data with meta analysis to investigate the preventive effect of 5-aminosalicylic acid( 5-ASA) on inflammatory bowel disease( IBD)-associated colorectal cancer( CRC) or dysplasia( Dys)( IBD-CRC /Dys). METHODS: The information was retrieved from the main databases such as PubMed,Web of Science,the Cochrane Library,etc. All full-text articles about the prevention of IBD-CRC /Dys by 5-ASA were included if they conformed to the standards. The odds ratio( OR) and its 95% confidence interval( CI) were calculated.According to the types of IBD and the treatment course,the subgroup analysis was conducted,respectively. RESULTS:Fifteen articles were selected,including 5 038 IBD patients. Pooled analysis showed a protective association between 5-ASA and IBD-CRC /Dys( OR = 0. 53,95% CI: 0. 37 ~ 0. 76). Among them,both ulcerative colitis patients( OR = 0. 45,95% CI: 0. 27 ~ 0. 77) and Crohn disease patients( OR = 0. 39,95% CI: 0. 16 ~ 0. 97) with 5-ASA therapy were less likely to develop CRC /Dys compared with those without 5-ASA treatment. 5-ASA treatment for 1 ~ 20 years shows a preventive benefit( OR = 0. 43,95% CI: 0. 25 ~ 0. 74). However,a minimum 5-ASA exposure of 2 ~ 6 months did not show a preventive benefit( OR = 0. 59,95% CI: 0. 26 ~ 1. 34). CONCLUSION: 5-ASA protects against CRC /Dys in IBD patients. Additionally,the protective effect is treatment time dependent. Treatment course for 1 ~ 20 years shows an evident preventive benefit.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2014年第10期1813-1819,共7页 Chinese Journal of Pathophysiology
基金 国家自然科学基金资助项目(No.81270477)
关键词 氨基水杨酸 炎症性肠疾病 结直肠肿瘤 Meta分析 Aminosalicylic acid Inflammatory bowel disease Colorectal neoplasms Meta-analysis
  • 相关文献

参考文献4

二级参考文献35

  • 1Bin WU Jie GAO Ming-wei WANG~2 The National Center for Drug Screening,Shanghai Institute of Materia Medica,Shanghai Institutes for Biological Sciences,Chinese Academy of Sciences,Graduate School of Chinese Academy of Sciences,Shanghai 201203,China.Development of a complex scintillation proximity assay for highthroughput screening of PPAR7 modulators[J].Acta Pharmacologica Sinica,2005,26(3):339-344. 被引量:12
  • 2[1]Waite RA,Malinowski JM.Possible mesalamine-induced pericarditis:case report and literature review.Pharmacotherapy 2002; 22:391-394
  • 3[2]Bansal D,Chahoud G,Ison K,Gupta E,Montgomery M,Garza L,Mehta JL.Pleuropericarditis and pericardial tamponade associated with inflammatory bowel disease.J Ark Med Soc 2005; 102:16-19
  • 4[3]Hyttinen L,Kaipiainen-Seppanen O,Halinen M.Recurrent myopericarditis in association with Crohn's disease.J Intern Med 2003; 253:386-388
  • 5[4]Su CG,Judge TA,Lichtenstein GR.Extraintestinal manifestations of inflammatory bowel disease.Gastroenterol Clin North Am 2002; 31:307-327
  • 6[5]Ishikawa N,Imamura T,Nakajima K,Yamaga J,Yuchi H,Ootsuka M,Inatsu H,Aoki T,Eto T.Acute pericarditis associated with 5-aminosalicylic acid (5-ASA) treatment for severe active ulcerative colitis.Intern Med 2001; 40:901-904
  • 7[6]Iaquinto G,Sorrentini I,Petillo FE,Berardesca G.Pleuropericarditis in a patient with ulcerative colitis in longstanding 5-aminosalicylic acid therapy.Ital J Gastroenterol 1994; 26:145-147
  • 8[7]Stein RB,Hanauer SB.Comparative tolerability of treatments for inflammatory bowel disease.Drug Saf 2000; 23:429-448
  • 9[8]Nielsen OH,Munck LK.Drug insight:aminosalicylates for the treatment of IBD.Nat Clin Pract Gastroenterol Hepatol 2007; 4:160-170
  • 10Reich K, Segaert S, Van de Kerkhof P, et al. Once- weekly administration of etanercept 50 mg improves pa- tient-reported outcomes in patients with moderate-to-severe plaque psoriasis [ J ]. Dermatology, 2009, 219 (3) : 239- 249.

共引文献40

同被引文献2

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部